1. Home
  2. TAL vs ICUI Comparison

TAL vs ICUI Comparison

Compare TAL & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TAL

TAL Education Group

HOLD

Current Price

$12.38

Market Cap

5.4B

Sector

Real Estate

ML Signal

HOLD

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$166.92

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAL
ICUI
Founded
2003
1984
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.6B
IPO Year
2010
1995

Fundamental Metrics

Financial Performance
Metric
TAL
ICUI
Price
$12.38
$166.92
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$11.15
$169.00
AVG Volume (30 Days)
3.7M
252.1K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.62
EPS
N/A
1.96
Revenue
N/A
$2,231,262,000.00
Revenue This Year
$22.97
N/A
Revenue Next Year
$17.08
$4.46
P/E Ratio
$23.36
$85.23
Revenue Growth
N/A
N/A
52 Week Low
$8.88
$112.50
52 Week High
$13.37
$192.85

Technical Indicators

Market Signals
Indicator
TAL
ICUI
Relative Strength Index (RSI) 59.13 39.73
Support Level $10.70 $164.09
Resistance Level $12.55 $191.07
Average True Range (ATR) 0.38 4.17
MACD -0.01 -2.68
Stochastic Oscillator 70.22 1.76

Price Performance

Historical Comparison
TAL
ICUI

About TAL TAL Education Group

TAL Education Group is a leading learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Share on Social Networks: